Li Yong, Liu Fenghua, Yang Liang, Meng Yan, Li Aijun, Pan Mianshun
Department of Radiation Oncology, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Center of Radiation Oncology, Wujing Hospital, Shanghai, China.
Asia Pac J Clin Oncol. 2019 Dec;15(6):316-322. doi: 10.1111/ajco.13194. Epub 2019 Jul 16.
Both surgery and external-beam radiotherapy are effective treatments for hepatocellular carcinoma (HCC) patients with inferior vena cava/right atrium (IVC/RA) tumor thrombi. At present, it is not clear which modality is more suitable. We therefore compared outcomes between surgery and radiotherapy for these patients.
We retrospectively reviewed 108 HCC patients with IVC/RA tumor thrombi who were referred for surgery (n = 51) and external-beam radiotherapy (n = 57) at three institutions. Different surgical methods were selected according to the classification of the tumor thrombus. Radiotherapy was designed to focus on primary intrahepatic tumors and tumor thrombi. Predictors of time to progression (TTP) were identified by using univariate and multivariate analyses.
The median TTP was significantly longer in the radiotherapy group than in the surgery group (5.0 months vs 4.2 months; P = 0.010). The multivariate analysis revealed that independent factors predicting shorter TTP were treatment with surgery (HR = 0.577; 95% CI, 0.385-0.865; P = 0.008) and intrahepatic tumor size larger than 10 cm (HR = 0.561; 95% CI, 0.342-0.919; P = 0.022). The median survival times for the radiotherapy and surgery groups were 12.8 and 14.5 months, respectively; the two groups did not have a significant difference in survival (P = 0.466).
For HCC patients with IVC/RA tumor thrombi, treatment with external-beam radiotherapy and intrahepatic tumor size smaller than 10 cm may predict longer TTP. Compared with complicated surgery, radiotherapy, as a noninvasive treatment modality, may be more likely to be accepted.
手术和外照射放疗都是治疗伴有下腔静脉/右心房(IVC/RA)肿瘤血栓的肝细胞癌(HCC)患者的有效方法。目前,尚不清楚哪种方式更合适。因此,我们比较了这些患者手术和放疗的疗效。
我们回顾性分析了在三家机构接受手术(n = 51)和外照射放疗(n = 57)的108例伴有IVC/RA肿瘤血栓的HCC患者。根据肿瘤血栓的分类选择不同的手术方法。放疗旨在聚焦肝内原发性肿瘤和肿瘤血栓。通过单因素和多因素分析确定疾病进展时间(TTP)的预测因素。
放疗组的中位TTP显著长于手术组(5.0个月对4.2个月;P = 0.010)。多因素分析显示,预测TTP较短的独立因素是接受手术治疗(HR = 0.577;95%CI,0.385 - 0.865;P = 0.008)和肝内肿瘤大小大于10 cm(HR = 0.561;95%CI,0.342 - 0.919;P = 0.022)。放疗组和手术组的中位生存时间分别为12.8个月和14.5个月;两组在生存方面无显著差异(P = 0.466)。
对于伴有IVC/RA肿瘤血栓的HCC患者,外照射放疗和肝内肿瘤大小小于10 cm可能预示着更长的TTP。与复杂的手术相比,放疗作为一种非侵入性治疗方式,可能更容易被接受。